View Future GrowthMayne Pharma Group 過去の業績過去 基準チェック /06Mayne Pharma Groupは12.6%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで9.7%毎年増加している。売上は成長しており、年平均5.1%の割合である。主要情報12.64%収益成長率12.87%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率5.08%株主資本利益率-23.31%ネット・マージン-20.19%前回の決算情報31 Dec 2025最近の業績更新お知らせ • Feb 19Mayne Pharma Group Limited to Report First Half, 2026 Results on Feb 23, 2026Mayne Pharma Group Limited announced that they will report first half, 2026 results on Feb 23, 2026お知らせ • Aug 01Mayne Pharma Group Limited to Report Fiscal Year 2025 Results on Aug 29, 2025Mayne Pharma Group Limited announced that they will report fiscal year 2025 results on Aug 29, 2025お知らせ • Feb 21+ 1 more updateMayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024Mayne Pharma Group Limited announced that they will report fiscal year 2024 results on Aug 23, 2024お知らせ • Feb 12Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024Mayne Pharma Group Limited announced that they will report first half, 2024 results on Feb 26, 2024お知らせ • Aug 24Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023Mayne Pharma Group Limited announced that they will report fiscal year 2023 results on Aug 31, 2023お知らせ • Feb 15+ 1 more updateMayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023Mayne Pharma Group Limited announced that they will report first half, 2023 results on Feb 28, 2023すべての更新を表示Recent updatesお知らせ • Feb 25+ 2 more updatesMayne Pharma Group Limited Announces CEO ChangesMayne Pharma Group Limited announced that on 20 February 2026 (US time) Mr. Shawn Patrick O'Brien stepped down as Chief Executive Officer, and Mr. Aaron Gray, currently Mayne Pharma's Chief Financial Officer, was appointed Chief Executive Officer. Mr. O'Brien joined Mayne Pharma as CEO and Managing Director in October 2022 and will remain available to the Board in an advisory capacity until May 1, 2026 to support an orderly transition to Mr. Aaron Gray as part of Mayne Pharma's structured succession process. Aaron Gray joined Mayne Pharma in July 2022 and has been the Chief Financial Officer since August 29, 2022. He brings over 20 years of experience to the role. Prior to joining Mayne Pharma, Aaron held senior finance roles at Siemens Healthineers, a leading global medical technology company with EUR20 billion in revenues and 48,000 employees globally. Most recently, he was Senior Vice President, USA Customer Finance with EUR5 billion in revenues. Prior to joining Siemens Healthineers, he spent 15 years in finance roles at Siemens AG energy divisions. Aaron has significant expertise in the areas of financial planning and analysis, strategy, digitisation, sales operations, manufacturing, risk management and operational excellence.お知らせ • Feb 19Mayne Pharma Group Limited to Report First Half, 2026 Results on Feb 23, 2026Mayne Pharma Group Limited announced that they will report first half, 2026 results on Feb 23, 2026お知らせ • Jan 15Mayne Pharma Receives Notice of Appeal Filed by Cosette and Its Bidco with the Supreme Court of New South Wales, Court of AppealMayne Pharma Group Limited refers to its announcement on 16 October 2025 relating to the judgment delivered on 15 October 2025 in which the Supreme Court of New South Wales found in favour of Mayne Pharma and its announcement on 10 November 2025 regarding a notice of intention to appeal filed by Cosette Pharmaceuticals Inc. (Cosette) and its BidCo. Mayne Pharma has received a notice of appeal filed by Cosette and its BidCo with the Supreme Court of New South Wales, Court of Appeal. The two grounds set out in the notice of appeal seek to challenge various of the Court's findings related to: Mayne Pharma's FY25 EBITDA the subject of Cosette's misleading and deceptive conduct claim; and Cosette's allegation that a Mayne Material Adverse Change had occurred on the basis of Cosette's pleaded Third Quarter FY25 Sales Performance Matters.お知らせ • Jan 14Mayne Pharma Group Limited Announces Board Changes Effective January 14, 2026Mayne Pharma Group Limited announced that the Board of Directors has decided to reduce the size of the Board. Mr. Frank Condella, Board Chair, will retire from the Board effective January 14, 2026. Mr. Condella has served as a director of Mayne Pharma since May 2018 and as Board Chair since September 2021. Non-Executive directors Mr. Patrick Blake and Mrs. Anne Lockwood will step down from the Board following the release of the Company’s half year results in February 2026 to focus on other opportunities. Mr. Blake has served as a director since June 2018. Mrs. Lockwood has served as a director since November 2023. Professor Bruce Robinson has been appointed as Non-Executive Chair of the Board effective January 14, 2026. Professor Robinson was appointed a Non-Executive Director of the Company in August 2014. He is a Non-Executive Director of Cochlear Limited and CS Pharmaceuticals Limited. He is formerly a Board Member of the Woolcock Institute, was Chair of the National Health and Medical Research Council and Chair of the Medical Benefits Review Taskforce. Professor Robinson is Chair of the Science, Technology and Medical Committee and a member of the Nomination Committee.お知らせ • Dec 22Mayne Pharma Group Limited, Annual General Meeting, Jan 29, 2026Mayne Pharma Group Limited, Annual General Meeting, Jan 29, 2026. Location: minter ellison office, level 20, collins arch, 447 collins st, and, melbourne Australiaお知らせ • Aug 01Mayne Pharma Group Limited to Report Fiscal Year 2025 Results on Aug 29, 2025Mayne Pharma Group Limited announced that they will report fiscal year 2025 results on Aug 29, 2025お知らせ • Apr 10TherapeuticsMD, Inc. Files Lawsuit Against Mayne Pharma for Contract BreachesOn April 8, 2025, TherapeuticsMD Inc., a Nevada corporation (the “Company”), filed a lawsuit against Mayne Pharma LLC (“Mayne Pharma”) in the United States District Court for the District of Delaware (the “Mayne Lawsuit”) seeking damages for breach of contract, breach of the implied covenant of good faith and fair dealing, fraudulent inducement, and unjust enrichment related to Mayne Pharma’s actions in relation to the License Agreement, dated December 4, 2022, as amended, between the Company and Mayne Pharma and the Transaction Agreement, dated December 4, 2022, as amended, between the Company and Mayne Pharma. The Mayne Lawsuit primarily pertains to the previously disclosed disputes between the Company and Mayne Pharma relating to certain net working capital allowances and certain actions or inactions by Mayne Pharma relating thereto. The Mayne Lawsuit is TherapeuticsMD Inc. v. Mayne Pharma LLC, Case No. not assigned (D. Del.).お知らせ • Feb 22Cosette Pharmaceuticals, Inc. agreed to acquire Mayne Pharma Group Limited (ASX:MYX) from Viburnum Funds Pty Ltd, Bruce Mathieson and others for approximately AUD 600 million.Cosette Pharmaceuticals, Inc. agreed to acquire Mayne Pharma Group Limited (ASX:MYX) from Viburnum Funds Pty Ltd, Bruce Mathieson and others for approximately AUD 600 million on February 20, 2025. A cash consideration of AUD 601.22 million valued at AUD 7.4 per share will be paid by Cosette Pharmaceuticals, Inc. As part of consideration, AUD 601.22 million is paid towards common equity of Mayne Pharma Group Limited. The transaction is subject to approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by target shareholders and subject to court approval. The deal has been unanimously approved by the board. The expected completion of the transaction is May 21, 2025 to June 10, 2025. Jefferies Pty Ltd acted as financial advisor for Mayne Pharma Group Limited. Arnold & Porter Kaye Scholer LLP acted as legal advisor for Mayne Pharma Group Limited. Gilbert and Tobin acted as legal advisor for Mayne Pharma Group Limited. Ropes & Gray LLP acted as legal advisor for Cosette Pharmaceuticals, Inc. Corrs Chambers Westgarth acted as legal advisor for Cosette Pharmaceuticals, Inc. UBS Securities LLC acted as financial advisor for Cosette Pharmaceuticals, Inc. Santander US Capital Markets LLC acted as financial advisor for Cosette Pharmaceuticals, Inc.お知らせ • Feb 10+ 1 more updateMayne Pharma Group Limited Provides Earnings Guidance for the First Half Ended 31 December 2024Mayne Pharma Group Limited provided earnings guidance for the first half ended 31 December 2024. For the period, the company expects revenues to be $210 million to $215 million, reflecting 12 - 14% growth on first half of 2024.お知らせ • Feb 21+ 1 more updateMayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024Mayne Pharma Group Limited announced that they will report fiscal year 2024 results on Aug 23, 2024お知らせ • Feb 12Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024Mayne Pharma Group Limited announced that they will report first half, 2024 results on Feb 26, 2024お知らせ • Nov 30Mayne Pharma Group Limited Approves Election of Anne LockwoodMayne Pharma Group Limited at its AGM approved election of Anne Lockwood.お知らせ • Oct 27Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023, at 10:00 AUS Eastern Standard Time. Location: MinterEllison Offices, Lvl 20, Collins Arch, 447 Collins St Melbourne Australia Agenda: To consider and approve the statutory reports for the financial year ended 30 June 2023; to consider and approve the election of Director; to consider and approve the remuneration report; to consider and approve the Short-Term Incentive grant of Restricted Stock Unit Performance Rights and a Long-Term Incentive grant of Performance Rights to the CEO and Managing Director; to consider and approve the appointment of BDO Audit Pty Ltd as the Company's auditor; and to consider and approve the extension of the on-market share buy-back.お知らせ • Aug 24Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023Mayne Pharma Group Limited announced that they will report fiscal year 2023 results on Aug 31, 2023お知らせ • Jul 27Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023Mayne Pharma Group Limited announced that Dr. Carolyn Myers will retire from the Board at the end of July 2023.Dr Myers has served as a Director of Mayne Pharma since October 2021. She was appointed to theBoard after being nominated by Mithra Pharmaceuticals SA under the terms of the license andsupply agreement to commercialise NEXTSTELLIS® (E4/DRSP) oral contraceptive in the UnitedStates.お知らせ • Feb 15+ 1 more updateMayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023Mayne Pharma Group Limited announced that they will report first half, 2023 results on Feb 28, 2023お知らせ • Jan 14Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of NuvaringMayne Pharma Group Limited and Mithra Pharmaceuticals, SA announced the launch of HALOETTE (etonogestrel and ethinyl estradiol) a vaginal hormonal contraceptive ring into the US market. HALOETTE contraceptive is a generic version of NUVARING, a combined hormonal contraceptive flexible ring indicated for the prevention of pregnancy. Under the terms of the long-term license and supply agreement, Mayne Pharma will pay Mithra a milestone of EUR 1.6 million.収支内訳Mayne Pharma Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:MAYN.F 収益、費用、利益 ( )AUD Millions日付収益収益G+A経費研究開発費31 Dec 25407-822722130 Sep 25408-862621930 Jun 25408-902511831 Mar 25411-1042601931 Dec 24414-1182682030 Sep 24401-1432722030 Jun 24388-1692762031 Dec 23319-2742721830 Sep 23251-2962621730 Jun 23184-3172511631 Dec 2259-2571931330 Sep 22108-2331871230 Jun 22157-2091821231 Mar 22250-1511841531 Dec 21342-931861930 Sep 21372-1511792030 Jun 21401-2081732231 Mar 21420-2321802231 Dec 20439-2561872230 Sep 20448-1741942430 Jun 20457-932002531 Mar 20467-1962102631 Dec 19478-3002202730 Sep 19502-2902312830 Jun 19525-2792412931 Mar 19543-1182302731 Dec 18561432192530 Sep 18546-462082030 Jun 18530-1341971531 Mar 18526-1461961231 Dec 17521-158194830 Sep 17547-35192830 Jun 1757389190831 Mar 1750490173831 Dec 1643591156830 Sep 1635164136730 Jun 1626737115731 Mar 1623830105731 Dec 152092394730 Sep 151751577630 Jun 151418604質の高い収益: MAYN.Fは現在利益が出ていません。利益率の向上: MAYN.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: MAYN.Fは利益を出していないが、過去 5 年間で年間12.6%の割合で損失を削減してきた。成長の加速: MAYN.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: MAYN.Fは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -5% ) と比較することは困難です。株主資本利益率高いROE: MAYN.Fは現在利益が出ていないため、自己資本利益率 ( -23.31% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 02:00終値2026/05/20 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Mayne Pharma Group Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関William DunlopBofA Global ResearchElyse ShapiroCanaccord GenuityJohn Deakin-BellCitigroup Inc2 その他のアナリストを表示
お知らせ • Feb 19Mayne Pharma Group Limited to Report First Half, 2026 Results on Feb 23, 2026Mayne Pharma Group Limited announced that they will report first half, 2026 results on Feb 23, 2026
お知らせ • Aug 01Mayne Pharma Group Limited to Report Fiscal Year 2025 Results on Aug 29, 2025Mayne Pharma Group Limited announced that they will report fiscal year 2025 results on Aug 29, 2025
お知らせ • Feb 21+ 1 more updateMayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024Mayne Pharma Group Limited announced that they will report fiscal year 2024 results on Aug 23, 2024
お知らせ • Feb 12Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024Mayne Pharma Group Limited announced that they will report first half, 2024 results on Feb 26, 2024
お知らせ • Aug 24Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023Mayne Pharma Group Limited announced that they will report fiscal year 2023 results on Aug 31, 2023
お知らせ • Feb 15+ 1 more updateMayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023Mayne Pharma Group Limited announced that they will report first half, 2023 results on Feb 28, 2023
お知らせ • Feb 25+ 2 more updatesMayne Pharma Group Limited Announces CEO ChangesMayne Pharma Group Limited announced that on 20 February 2026 (US time) Mr. Shawn Patrick O'Brien stepped down as Chief Executive Officer, and Mr. Aaron Gray, currently Mayne Pharma's Chief Financial Officer, was appointed Chief Executive Officer. Mr. O'Brien joined Mayne Pharma as CEO and Managing Director in October 2022 and will remain available to the Board in an advisory capacity until May 1, 2026 to support an orderly transition to Mr. Aaron Gray as part of Mayne Pharma's structured succession process. Aaron Gray joined Mayne Pharma in July 2022 and has been the Chief Financial Officer since August 29, 2022. He brings over 20 years of experience to the role. Prior to joining Mayne Pharma, Aaron held senior finance roles at Siemens Healthineers, a leading global medical technology company with EUR20 billion in revenues and 48,000 employees globally. Most recently, he was Senior Vice President, USA Customer Finance with EUR5 billion in revenues. Prior to joining Siemens Healthineers, he spent 15 years in finance roles at Siemens AG energy divisions. Aaron has significant expertise in the areas of financial planning and analysis, strategy, digitisation, sales operations, manufacturing, risk management and operational excellence.
お知らせ • Feb 19Mayne Pharma Group Limited to Report First Half, 2026 Results on Feb 23, 2026Mayne Pharma Group Limited announced that they will report first half, 2026 results on Feb 23, 2026
お知らせ • Jan 15Mayne Pharma Receives Notice of Appeal Filed by Cosette and Its Bidco with the Supreme Court of New South Wales, Court of AppealMayne Pharma Group Limited refers to its announcement on 16 October 2025 relating to the judgment delivered on 15 October 2025 in which the Supreme Court of New South Wales found in favour of Mayne Pharma and its announcement on 10 November 2025 regarding a notice of intention to appeal filed by Cosette Pharmaceuticals Inc. (Cosette) and its BidCo. Mayne Pharma has received a notice of appeal filed by Cosette and its BidCo with the Supreme Court of New South Wales, Court of Appeal. The two grounds set out in the notice of appeal seek to challenge various of the Court's findings related to: Mayne Pharma's FY25 EBITDA the subject of Cosette's misleading and deceptive conduct claim; and Cosette's allegation that a Mayne Material Adverse Change had occurred on the basis of Cosette's pleaded Third Quarter FY25 Sales Performance Matters.
お知らせ • Jan 14Mayne Pharma Group Limited Announces Board Changes Effective January 14, 2026Mayne Pharma Group Limited announced that the Board of Directors has decided to reduce the size of the Board. Mr. Frank Condella, Board Chair, will retire from the Board effective January 14, 2026. Mr. Condella has served as a director of Mayne Pharma since May 2018 and as Board Chair since September 2021. Non-Executive directors Mr. Patrick Blake and Mrs. Anne Lockwood will step down from the Board following the release of the Company’s half year results in February 2026 to focus on other opportunities. Mr. Blake has served as a director since June 2018. Mrs. Lockwood has served as a director since November 2023. Professor Bruce Robinson has been appointed as Non-Executive Chair of the Board effective January 14, 2026. Professor Robinson was appointed a Non-Executive Director of the Company in August 2014. He is a Non-Executive Director of Cochlear Limited and CS Pharmaceuticals Limited. He is formerly a Board Member of the Woolcock Institute, was Chair of the National Health and Medical Research Council and Chair of the Medical Benefits Review Taskforce. Professor Robinson is Chair of the Science, Technology and Medical Committee and a member of the Nomination Committee.
お知らせ • Dec 22Mayne Pharma Group Limited, Annual General Meeting, Jan 29, 2026Mayne Pharma Group Limited, Annual General Meeting, Jan 29, 2026. Location: minter ellison office, level 20, collins arch, 447 collins st, and, melbourne Australia
お知らせ • Aug 01Mayne Pharma Group Limited to Report Fiscal Year 2025 Results on Aug 29, 2025Mayne Pharma Group Limited announced that they will report fiscal year 2025 results on Aug 29, 2025
お知らせ • Apr 10TherapeuticsMD, Inc. Files Lawsuit Against Mayne Pharma for Contract BreachesOn April 8, 2025, TherapeuticsMD Inc., a Nevada corporation (the “Company”), filed a lawsuit against Mayne Pharma LLC (“Mayne Pharma”) in the United States District Court for the District of Delaware (the “Mayne Lawsuit”) seeking damages for breach of contract, breach of the implied covenant of good faith and fair dealing, fraudulent inducement, and unjust enrichment related to Mayne Pharma’s actions in relation to the License Agreement, dated December 4, 2022, as amended, between the Company and Mayne Pharma and the Transaction Agreement, dated December 4, 2022, as amended, between the Company and Mayne Pharma. The Mayne Lawsuit primarily pertains to the previously disclosed disputes between the Company and Mayne Pharma relating to certain net working capital allowances and certain actions or inactions by Mayne Pharma relating thereto. The Mayne Lawsuit is TherapeuticsMD Inc. v. Mayne Pharma LLC, Case No. not assigned (D. Del.).
お知らせ • Feb 22Cosette Pharmaceuticals, Inc. agreed to acquire Mayne Pharma Group Limited (ASX:MYX) from Viburnum Funds Pty Ltd, Bruce Mathieson and others for approximately AUD 600 million.Cosette Pharmaceuticals, Inc. agreed to acquire Mayne Pharma Group Limited (ASX:MYX) from Viburnum Funds Pty Ltd, Bruce Mathieson and others for approximately AUD 600 million on February 20, 2025. A cash consideration of AUD 601.22 million valued at AUD 7.4 per share will be paid by Cosette Pharmaceuticals, Inc. As part of consideration, AUD 601.22 million is paid towards common equity of Mayne Pharma Group Limited. The transaction is subject to approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by target shareholders and subject to court approval. The deal has been unanimously approved by the board. The expected completion of the transaction is May 21, 2025 to June 10, 2025. Jefferies Pty Ltd acted as financial advisor for Mayne Pharma Group Limited. Arnold & Porter Kaye Scholer LLP acted as legal advisor for Mayne Pharma Group Limited. Gilbert and Tobin acted as legal advisor for Mayne Pharma Group Limited. Ropes & Gray LLP acted as legal advisor for Cosette Pharmaceuticals, Inc. Corrs Chambers Westgarth acted as legal advisor for Cosette Pharmaceuticals, Inc. UBS Securities LLC acted as financial advisor for Cosette Pharmaceuticals, Inc. Santander US Capital Markets LLC acted as financial advisor for Cosette Pharmaceuticals, Inc.
お知らせ • Feb 10+ 1 more updateMayne Pharma Group Limited Provides Earnings Guidance for the First Half Ended 31 December 2024Mayne Pharma Group Limited provided earnings guidance for the first half ended 31 December 2024. For the period, the company expects revenues to be $210 million to $215 million, reflecting 12 - 14% growth on first half of 2024.
お知らせ • Feb 21+ 1 more updateMayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024Mayne Pharma Group Limited announced that they will report fiscal year 2024 results on Aug 23, 2024
お知らせ • Feb 12Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024Mayne Pharma Group Limited announced that they will report first half, 2024 results on Feb 26, 2024
お知らせ • Nov 30Mayne Pharma Group Limited Approves Election of Anne LockwoodMayne Pharma Group Limited at its AGM approved election of Anne Lockwood.
お知らせ • Oct 27Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023, at 10:00 AUS Eastern Standard Time. Location: MinterEllison Offices, Lvl 20, Collins Arch, 447 Collins St Melbourne Australia Agenda: To consider and approve the statutory reports for the financial year ended 30 June 2023; to consider and approve the election of Director; to consider and approve the remuneration report; to consider and approve the Short-Term Incentive grant of Restricted Stock Unit Performance Rights and a Long-Term Incentive grant of Performance Rights to the CEO and Managing Director; to consider and approve the appointment of BDO Audit Pty Ltd as the Company's auditor; and to consider and approve the extension of the on-market share buy-back.
お知らせ • Aug 24Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023Mayne Pharma Group Limited announced that they will report fiscal year 2023 results on Aug 31, 2023
お知らせ • Jul 27Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023Mayne Pharma Group Limited announced that Dr. Carolyn Myers will retire from the Board at the end of July 2023.Dr Myers has served as a Director of Mayne Pharma since October 2021. She was appointed to theBoard after being nominated by Mithra Pharmaceuticals SA under the terms of the license andsupply agreement to commercialise NEXTSTELLIS® (E4/DRSP) oral contraceptive in the UnitedStates.
お知らせ • Feb 15+ 1 more updateMayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023Mayne Pharma Group Limited announced that they will report first half, 2023 results on Feb 28, 2023
お知らせ • Jan 14Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of NuvaringMayne Pharma Group Limited and Mithra Pharmaceuticals, SA announced the launch of HALOETTE (etonogestrel and ethinyl estradiol) a vaginal hormonal contraceptive ring into the US market. HALOETTE contraceptive is a generic version of NUVARING, a combined hormonal contraceptive flexible ring indicated for the prevention of pregnancy. Under the terms of the long-term license and supply agreement, Mayne Pharma will pay Mithra a milestone of EUR 1.6 million.